Anti-BRD3 antibody [BLR069G],Abcam,AB264420
REACH authorisation Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances. It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses. This product is sold under License from Bethyl Laboratories, Inc.
Host
Rabbit
Reactivity
Human
Application
IP, IHC-P, ICC, WB, Flow Cyt
Platform ID
BAB731882994
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Chromatin reader that recognizes and binds acetylated histones, thereby controlling gene expression and remodeling chromatin structures (PubMed : 18406326, PubMed : 22464331, PubMed : 27105114, PubMed : 32895492). Recruits transcription factors and coactivators to target gene sites, and activates RNA polymerase II machinery for transcriptional elongation (PubMed : 29567837, PubMed : 32895492). In vitro, binds acetylated lysine residues on the N-terminus of histone H2A, H2B, H3 and H4 (PubMed : 18406326). Involved in endoderm differentiation via its association with long non-coding RNA (lncRNA) DIGIT : BRD3 undergoes liquid-liquid phase separation upon binding to lncRNA DIGIT, promoting binding to histone H3 acetylated at 'Lys-18' (H3K18ac) to induce endoderm gene expression (PubMed : 32895492). Also binds non-histones acetylated proteins, such as GATA1 and GATA2 : regulates transcription by promoting the binding of the transcription factor GATA1 to its targets (By similarity). See full target information BRD3
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.